Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the Treating to New Targets Study)

American Journal of Cardiology

Volumn 113, Issue 10, 2014, Pages 1593-1598

  Ong, Kwok Leung ^a,b   Waters, David D ^c   Messig, Michael ^d   Demicco, David A ^d   Rye, Kerry Anne ^a,b   Barter, Philip J ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INCIDENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; WEIGHT CONTROL;

BODY WEIGHT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; PYRROLES; RISK FACTORS; TIME FACTORS; WEIGHT LOSS; WORLD HEALTH;

EID: 84899911844     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.02.011     Document Type: Article

References (14)

1. D.D. Waters, J.R. Guyton, D.M. Herrington, M.P. McGowan, N.K. Wenger, C. Shear TNT Steering Committee Members and Investigators Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 93 2004 154 158
2. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, J. Shepherd, N.K. Wenger Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
3. A.J. Hanley, K. Williams, A. Festa, L.E. Wagenknecht, R.B. D'Agostino Jr., and S.M. Haffner Liver markers and development of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study Diabetes 54 2005 3140 3147
4. B. Vozarova, N. Stefan, R.S. Lindsay, A. Saremi, R.E. Pratley, C. Bogardus, and P.A. Tataranni High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes Diabetes 51 2002 1889 1895
5. N. Sattar, O. Scherbakova, I. Ford, D.S. O'Reilly, A. Stanley, E. Forrest, P.W. Macfarlane, C.J. Packard, S.M. Cobbe, J. Shepherd West of Scotland coronary prevention study Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study Diabetes 53 2004 2855 2860
6. E.S. Ford, M.B. Schulze, M.M. Bergmann, C. Thamer, H.G. Joost, and H. Boeing Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study Diabetes Care 31 2008 1138 1143
7. K.K. Sato, T. Hayashi, Y. Nakamura, N. Harita, T. Yoneda, G. Endo, and H. Kambe Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare Study Diabetes Care 31 2008 1230 1236
8. A. Fraser, R. Harris, N. Sattar, S. Ebrahim, G. Davey Smith, and D.A. Lawlor Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis Diabetes Care 32 2009 741 750
9. D.D. Waters, J.E. Ho, D.A. DeMicco, A. Breazna, B.J. Arsenault, C.C. Wun, J.J. Kastelein, H. Colhoun, and P. Barter Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials J Am Coll Cardiol 57 2011 1535 1545
10. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, and I. Ford Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
11. S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Smith Jr., J.A. Spertus, F. Costa American Heart Association; National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2005 2735 2752
12. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, D.D. Waters, D.A. DeMicco, P. Barter, C.P. Cannon, M.S. Sabatine, E. Braunwald, J.J. Kastelein, J.A. de Lemos, M.A. Blazing, T.R. Pedersen, M.J. Tikkanen, N. Sattar, and K.K. Ray Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
13. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
14. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, and R. Collins Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681